Therapy Areas: Cardiovascular
Pentixapharm advances preparationsfor Phase 3 PANDA study
4 November 2026 - Biotechnology company Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) on Wednesday reported further progress towards its pivotal Phase 3 PANDA study, with US ethics approval ...
Abbott's Amulet 360 shows high LAA closure rates and low stroke incidence at one year
2 November 2026 - Healthcare company Abbott (NYSE: ABT) reported on Monday that it has achieved positive one-year results from the pivotal VERITAS study of its investigational Amulet 360 Left Atrial A...
Abbott reports 30-day results from clinical trial of SonicForce Coronary IVL System
2 November 2026 - US healthcare company Abbott (NYSE:ABT) on Sunday reported strong 30-day results from the TECTONIC Coronary Artery Disease (CAD) Intravascular Lithotripsy (IVL) Investigational Devic...
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
29 October 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Thursday that it has received European Medicines Agency (EMA) validation for two marketing authorisation app...
Ascletis reports positive US Phase II topline results for ASC30 in diabetes
29 October 2026 - Chinese pharmaceutical company Ascletis Pharma Inc (HKEX:1672) on Wednesday reported positive topline results from its US Phase II study evaluating ASC30, an oral small molecule GLP-...
Edwards Lifesciences wins FDA approval for PASCAL Precision tricuspid repair system
21 October 2026 - Edwards Lifesciences Corporation (NYSE: EW), a structural heart innovation company, announced on Wednesday that it has received US Food and Drug Administration (FDA) approval for its...